기자가 쓴 기사 더보기

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.
| 인기기사 | 더보기 + |
| 1 | 'BIO USA 2026' 앞두고 K-제약바이오 '들썩' |
| 2 | '메트포민 우선' 공식 깨졌다…당뇨병 치료,환자 맞춤형 초기 치료 시대로 전환 |
| 3 | [마이크로바이옴은 살아있다⑥] HEM파마 지요셉 대표 “데이터·제조·사업화 구조 완성…글로벌 집중 공략” |
| 4 | [기고] 김 변호사의 쉽게 읽는 바이오 ③큐리언트 |
| 5 | 아울바이오,인체 임상 성공 '월 1회 비만 치료제' 기술 마케팅 시동 |
| 6 | 상장 제약·바이오사 1Q 평균 R&D비용 코스피 184억원, 코스닥 31억원 달성 |
| 7 | 상장 제약·바이오사 1Q 평균 해외매출·수출액 코스피 810억, 코스닥 116억 달성 |
| 8 | 상장 제약·바이오사 1Q 평균 상품매출 코스피 448억, 코스닥 85억 달성 |
| 9 | [분석] 커지는 CSO, 달라지는 유통 생태계…엇갈리는 업계 시선 |
| 10 | "건강보험 마지막 퍼즐 맞췄다" 큐로셀 '림카토' 혈액학 권위지 Blood 게재 |
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |

[편집자 주 - 너무 어린 아이들이 강력한 향정신성 의약품에 쉽게 노출되어 있다는 기사입니다]
At 18 months, Kyle Warren started taking a daily antipsychotic drug on the orders of a pediatrician to quell the boy's severe tempter tantrums.
Thus began a troubled toddler's journey from one doctor to another, from one diagnosis to another, involving even more drugs. Autism, bipolar disorder, hyperactivity, insomnia, oppositional defiant disorder. The boy's daily pill regimen multiplied: the antipsychotic Risperdal [리스페달], the antidepressant Prozac [프로작], two sleeping medicines and one for attention-deficit disorder. All by the time he was 3.
He was sedated, drooling and overweight from the side effects of the antipsychotic medicine. Although his mother, Brandy Warren, had been at her "wit's end" when she resorted to the drug treatment, she began to worry about Kyle's altered personality.
"All I had was a medicated little boy," Ms. Warren said. "I didn't have my son. It's like, you'd look into his eyes, and you would just see just blankness."
Today, Kyle, 6, is in his forth week of first grade, scoring high marks on his first tests. He is rambunctious and much thinner. Weaned off the drugs through a program affiliated with Tulane University in New Orleans [U.S.A.] that is aimed at helping low-income families whose children have mental health problems, Kyle now laughs easily and teases his family.
Ms. Warren and Kyle's new doctors point to his remarkable progress - and a more common diagnosis for children of attention-deficit hyperactivity disorder - as proof that he should have never been prescribed such powerful drugs in the first place.